Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich melanocyte differentiation-associated protein (LRMDA)
- Target
- LRMDA
- Molecular classification
- Other (Leucine-rich repeat protein; not classified as receptor, ion channel, transporter, enzyme, or transcription factor; instead, it is a structural motif protein involved in cell differentiation), Leucine-rich repeat domain superfamily
01
Overview
Leucine-rich melanocyte differentiation-associated protein (LRMDA) is a member of the leucine-rich repeat protein family and is required for normal melanocyte differentiation, playing a critical role in pigmentation processes. It contains leucine-rich repeat domains that likely mediate protein-protein interactions vital for development and function of melanocytes, particularly in the neural crest. Mutations in LRMDA lead to autosomal recessive oculocutaneous albinism type VII (OCA7), characterized by markedly decreased pigment in the skin, hair, and eyes due to melanocyte dysfunction. The protein is not a receptor, enzyme, or drug target, but is essential for cell lineage specification. There are no known therapeutic agents targeting LRMDA directly, and it is mainly of diagnostic relevance in the genetics of albinism
- Other names
- LRMDAC10orf11CDA017OCA7Chromosome 10 open reading frame 11Leucine-rich repeat-containing protein C10orf11Oculocutaneous albinism 7, autosomal recessive
02
Mechanism of action
Not applicable (no current drugs or agents act on LRMDA)
03
Biological functions
Melanocyte differentiationPigmentation (acts upstream or within pigmentation pathways)Cellular development (acts during neural crest development, which gives rise to melanocytes)May influence disease phenotype through cell differentiation pathways
04
Disease associations
Oculocutaneous albinism type VII (OCA7), autosomal recessive (mutations in LRMDA result in this albinism subtype)Other rare pigmentation disorders
05
Safety considerations
No known safety concerns or therapeutic challenges directly related to LRMDA manipulation, because it is not a drug targetThe main clinical concern is risk of pigmentation defects (albinism) if mutated
06
Biomarkers
Genetic testing for mutations in LRMDA may serve as a biomarker for diagnosing OCA7 in affected patientsNo established biomarkers for patient selection or therapeutic efficacy monitoring
Beyond the preview
Go deeper on Leucine-rich melanocyte differentiation-associated protein (LRMDA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich melanocyte differentiation-associated protein (LRMDA).